Dupilumab suppression of Th2 biomarkers correlates with reduction in transepidermal water loss (TEWL) and clinical improvements in adults with moderate-to-severe atopic dermatitis (AD)

被引：0
|
作者：
Hamilton, J. [1 ]
Hamon, S. [1 ]
Chaudhry, U. [1 ]
Simpson, E. L. [2 ]
Swanson, B. [3 ]
Liu, M. [4 ]
Ren, H. [4 ]
Graham, N. [1 ]
Pirozzi, G. [3 ]
Ardeleanu, M. [1 ]
机构：
[1] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[2] Oregon Hlth & Sci Univ, Portland, OR USA
[3] Sanofi, Bridgewater, NJ USA
[4] Regeneron Pharmaceut Inc, Basking Ridge, NJ USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
169
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [21] Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to 5 years with moderate-to-severe atopic dermatitis
    Paller, A.
    Guttman-Yassky, E.
    Boguniewicz, M.
    Levit, N.
    Wolfe, K.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S250 - S250
  • [22] Dupilumab treatment provides improvements in signs of atopic dermatitis (AD) at week 100 in adult patients with moderate-to-severe AD who did not achieve ≥ 75% reduction in Eczema Area and Severity Index at week 16
    Armstrong, A.
    Blauvelt, A.
    Simpson, E. L.
    Chen, Z.
    Ardeleanu, M.
    Rossi, A. B.
    Tomondy, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E68 - E69
  • [23] Safety of dupilumab in moderate-to-severe atopic dermatitis: Clinical laboratory results from three phase 3 clinical trials (LIBERTY AD: SOLO 1, SOLO 2 and CHRONOS)
    Wollenberg, A.
    Blauvelt, A.
    Simpson, E. L.
    Chen, Z.
    Shumel, B.
    Khokhar, F. A.
    Hultsch, T.
    Rizova, E.
    Rossi, A.
    Graham, N. M. H.
    Pirozzi, G.
    Lu, Y.
    Ardeleanu, M.
    ALLERGY, 2018, 73 : 77 - 78
  • [24] Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (vol 157, pg 1047, 2021)
    Blauvelt, A.
    Teixeira, H. D.
    Simpson, E. L.
    JAMA DERMATOLOGY, 2022,
  • [25] Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (vol 157, pg 1047, 2021)
    Blauvelt, A.
    JAMA DERMATOLOGY, 2022, 158 (02) : 219 - 219
  • [26] Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (vol 157, pg 1047, 2021)
    Blauvelt, A.
    JAMA DERMATOLOGY, 2024, 160 (09) : 1012 - 1012
  • [27] Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (vol 157, pg 1047, 2021)
    Blauvelt, A.
    Teixeira, H. D.
    Simpson, E. L.
    JAMA DERMATOLOGY, 2024, 160 (03) : 370 - 370
  • [28] Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)
    Thaci, Diamant
    Simpson, Eric L.
    Deleuran, Mette
    Kataoka, Yoko
    Chen, Zhen
    Gadkari, Abhijit
    Eckert, Laurent
    Akinlade, Bolanle
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2019, 94 (02) : 266 - 275
  • [29] Dupilumab Reduces Biomarkers Indicative of Type 2 Inflammation in Children Aged ≥ 6 Months to < 6 YearsWith Moderate-to-Severe Atopic Dermatitis
    Pinter, Andreas
    Paller, Amy
    Guttman-Yassky, Emma
    Boguniewicz, Mark
    Sun, Yiping
    Wolfe, Kelley
    Dillon, Myles
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 100 - 100
  • [30] Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis
    Paller, A.
    Guttman-Yassky, E.
    Boguniewicz, M.
    Sun, Y.
    Wolfe, K.
    Dillon, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S51 - S51
12345